Sesame
Sesame is a direct-to-patient telehealth marketplace that connects patients with independent, licensed healthcare providers for virtual and in-person appointments. Founded in 2018, it operates on a cash-pay model with transparent pricing set by individual providers, covering primary care, mental health, dermatology, weight loss, and over 45 specialties. The platform does not accept insurance, positioning itself as an affordable alternative to insurance-based healthcare.
Score generated by AI agents based on publicly cited evidence and reviewed by the project maintainer. Not independently validated.
Score History
Timeline events are AI-curated from public reporting. Score trajectory is derived from documented events.
Sesame launched as EasyCare Health with a mission-driven direct-pay model, operating in two small markets (Kansas City and Oklahoma City) with nearly all in-person visits. The founding team brought healthcare policy expertise (Michael Botta, Harvard health economics PhD) and Goldhill's Leapfrog Group governance credentials. With minimal user base and no subscription products, the platform had almost no enshittification vectors.
The COVID-19 pandemic forced a rapid pivot to virtual care, growing the platform 25x in one year from two local markets to 48 states. Sesame raised capital from General Catalyst and partnered with NantHealth to scale the provider network. The growth was largely positive for users (wider access, more providers), but the rapid scaling introduced early marketplace quality inconsistencies as provider vetting struggled to keep pace.
Sesame expanded from pure marketplace to platform with SesameRx pharmacy, Sesame Plus membership, Sesame for Employers, and the $27M GV-led Series B. The membership model introduced subscription complexity that generated early BBB billing complaints. A 2022 academic study found third-party tracking pixels on Sesame's site leaking PHI to Google Analytics, Facebook Pixel, and Heap Analytics. VC funding reached $75M, adding board-level investor pressure from GV.
The Costco partnership (September 2023) and Success by Sesame weight loss program (August 2024) expanded Sesame's user base and service complexity. Subscription billing complaints intensified on BBB, with users reporting phantom subscriptions, post-no-show auto-billing, and cancellation difficulties. Provider no-shows and short messaging windows emerged as recurring user complaints. Despite these growing pains, the core marketplace model remained transparent and low-cost.
Alternatives
Mark Cuban's transparent-pricing pharmacy with cost-plus-15% markup and $5 dispensing fee. No telehealth consultations, so you'd need a separate provider for prescriptions, but dramatically lower medication costs with full pricing transparency.
Prescription discount platform with telehealth consultations that also accepts insurance. Broader pharmacy network and drug pricing tools. Easy switch -- just book a visit. Better for users who want insurance integration and medication savings across pharmacies.
Dimensional Breakdown
Summaries below were written by AI agents based on the cited evidence. They are editorial interpretations, not independent research findings.
Dimension History
Timeline (28 events)
Sesame founded as EasyCare Health in New York
David Goldhill, Michael Botta PhD, and John Fontein co-founded the company as EasyCare Health, later renamed Sesame. Goldhill drew on his 2009 Atlantic article 'How American Health Care Killed My Father' and his book 'Catastrophic Care' to build a direct-pay healthcare marketplace bypassing insurance intermediaries. The company raised $4.96M in seed funding.
Sesame launches in-person marketplace in two cities
Sesame launched its direct-pay healthcare marketplace in Kansas City and Oklahoma City, connecting patients with local providers for in-person visits at transparent, cash-pay prices. Nearly 100% of business came through in-person appointments, with the platform targeting uninsured Americans and those with high-deductible plans.
Sesame builds virtual care platform in five days during COVID
As the COVID-19 pandemic shut down in-person care, Sesame's team built a virtual appointment system from wireframe to live service in five days. The pivot leveraged Google Kubernetes Engine and Cloud SQL infrastructure, allowing rapid expansion from 2 local markets to 35 states within two weeks. Virtual appointments quickly grew to represent 86% of bookings.
Sesame announces national marketplace availability
Sesame formally announced its availability as a national direct-to-patient marketplace, operating across 48 states with both virtual and in-person care. The platform had grown 25x during the pandemic year and added over 1,000 new providers across all 50 states. Dr. Marty Makary, Johns Hopkins surgeon, served as Chief Medical Officer.
Sesame partners with NantHealth for provider network expansion
Sesame announced a collaboration with NantHealth, integrating with the NaviNet payer-provider platform used by thousands of healthcare providers. The partnership gave Sesame access to a large network of providers who could offer direct-pay care through the marketplace, while providers could increase practice revenue up to 25% per visit by reducing administrative costs.
Sesame raises $24M to expand nationwide telehealth
Sesame raised $24 million from new investors Giant Ventures, Industry Ventures, and Coefficient Capital, with existing backers General Catalyst, Entree Capital, and Atreides Management contributing. The round brought total capital raised to nearly $50 million. Funds were earmarked for expanding nationwide telehealth offerings and growing the provider network.
SesameRx digital pharmacy launches with $5 generics
Sesame unveiled SesameRx, an online pharmacy offering nearly 200 FDA-approved generic medications at $5 each with free nationwide shipping. The pharmacy was powered by Truepill, a URAC-accredited digital pharmacy platform. Patients could receive prescriptions during Sesame consultations and have medications shipped in two days, covering conditions from allergies to diabetes to ADHD.
Sesame Plus membership program launches in beta
Sesame introduced its Sesame Plus membership in beta, offering subscribers additional savings on marketplace services. Members booked 33% more appointments than non-members. The subscription model added a recurring revenue stream alongside the core pay-per-visit business, though it also introduced the subscription management complexity that would later generate billing complaints.
Sesame partners with TeleDentists for dental-medical integration
Sesame and The TeleDentists announced a partnership to offer virtual dental consultations 24/7/365 nationwide on the Sesame platform, with triage to in-person specialists when needed. The initiative expanded Sesame's service range beyond medical care into dental, further diversifying the marketplace offering.
Sesame named to NYC Digital Health 100 second consecutive year
Sesame was named to the NYC Digital Health 100 list by New York City Health Business Leaders for the second consecutive year, recognizing it among the most innovative digital health startups in the New York region. The recognition followed the company's rapid growth from a two-city marketplace to a national platform serving hundreds of thousands of patients.
Sesame for Employers launches at $20/employee/month
Sesame rolled out Sesame for Employers, providing health care benefits to small and medium-sized businesses at $20 per employee per month. The service included unlimited telehealth visits, primary care, urgent/sick visits, prescription refill appointments, and access to SesameRx. Sesame claimed the employer product was 95% cheaper than traditional managed care insurance.
Sesame secures $27M Series B led by Google Ventures
Sesame closed a $27 million Series B round led by GV (Google Ventures), with new investors Virgin Group, TeleSoft Partners, and FMZ Ventures. Cathy Friedman, Executive Venture Partner at GV, joined Sesame's board. The round brought total funding to $75 million and was earmarked to transition the Sesame Plus membership from beta to general availability.
Research study identifies third-party PHI leakage on Sesame
An academic study presented at ACM WPES 2022 found that Sesame's website leaked Protected Health Information to third parties through tracking technologies. Specifically, Google Analytics, DoubleClick, and Facebook Pixel received appointment dates, while the Heap Analytics service leaked patient names, gender, insurance provider, credit card digits, health provider histories, prescriptions, and appointment topics. All four telehealth sites studied leaked PHI.
Sesame @ Work launches for high-deductible health plans
Sesame unveiled Sesame @ Work, targeting employees enrolled in high-deductible health plans (HDHPs). Unlike Sesame for Employers, this product cost employers nothing — no flat fees and no per-member/per-month costs. Employees could apply Sesame expenditures toward their annual insurance deductible, and a loyalty program credited users for repeat visits.
Sesame @ Work announces first enterprise partners
Sesame announced Ameriplan, Tandem, and YouDecide as its first Sesame @ Work partners, bringing the zero-cost employer healthcare benefit to small and medium businesses. The product allowed employees to use their health savings accounts and flexible spending accounts on Sesame marketplace services.
FTC and HHS warn telehealth providers about tracking technologies
The FTC and HHS jointly sent letters to approximately 130 hospital systems and telehealth providers warning about privacy and security risks from online tracking technologies like Meta Pixel and Google Analytics. The warning followed the 2022 academic research that had identified PHI leakage on telehealth platforms including Sesame. The agencies reiterated that HIPAA rules apply to data collected through tracking technologies.
Sesame raises additional $10.1M Series B extension
Sesame raised a $10.1 million extension to its Series B round, bringing total funding to $84.8 million across four rounds from 13 institutional investors. The capital came weeks before the Costco partnership announcement, providing runway for the significant customer acquisition the Costco deal would bring.
Costco partnership launches with $29 virtual primary care
Sesame and Costco announced a partnership offering Costco members discounted healthcare services: $29 virtual primary care visits, $79 mental health therapy, and $72 health checkups including lab work. The deal gave Sesame access to Costco's 70+ million member base and represented a significant customer acquisition channel. Members also received 10% off all other Sesame services.
Costco weight loss program expansion with GLP-1 access
Sesame expanded its Costco partnership to include specialized weight loss care at $179 for Costco members. The program included three months of clinical consultation with a patient-selected clinician, video consultations, inter-appointment messaging, a nutritional guide, and when clinically appropriate, prescriptions for weight loss medications including Ozempic and Wegovy.
Success by Sesame launches compounded semaglutide at cost
Sesame unveiled Success by Sesame, a direct-to-consumer weight loss program offering compounded semaglutide at $249/month with no retail markup. The company selected a 503B compounding pharmacy and passed through medication costs to patients. The program included 14 prescription options beyond compounded semaglutide, including FDA-approved GLP-1s like Wegovy and Zepbound.
Sesame becomes first to offer compounded semaglutide in all 50 states
Sesame announced availability of compounded semaglutide in Alabama, California, Louisiana, and Mississippi, completing nationwide coverage across all 50 states. The company became the first major direct-to-consumer weight loss company to offer the compounded GLP-1 medication nationally, undercutting competitors in geographic reach.
Sesame CMO Marty Makary nominated as FDA commissioner
President-elect Trump nominated Dr. Martin Makary, Sesame's Chief Medical Officer, to lead the FDA. The nomination raised conflict-of-interest concerns given Sesame's compounded semaglutide business would be directly affected by FDA decisions on drug shortage lists and compounding regulations. Makary subsequently resigned from his Sesame role ahead of confirmation hearings.
Sesame offers free telehealth for LA wildfire victims
Sesame made zero-cost virtual healthcare appointments available to Los Angeles residents affected by January 2025 wildfires, including free telehealth visits, prescription refill appointments, and online therapy. The company coordinated with its provider network to waive all fees for impacted patients, demonstrating community response capabilities of the marketplace model.
FDA declares semaglutide shortage over, threatening compounding model
The FDA officially declared the Ozempic and Wegovy shortage resolved, which jeopardized Sesame's compounded semaglutide business. Under FDA rules, compounded versions of drugs are generally only permitted when branded versions are in shortage. The decision created regulatory uncertainty for Sesame's Success by Sesame weight loss program and other telehealth providers offering compounded GLP-1s.
Sesame integrates Zepbound through LillyDirect partnership
Sesame announced a technical integration with Gifthealth, the LillyDirect Self-Pay Pharmacy Solutions dispensing provider, to streamline access to Eli Lilly's Zepbound obesity medication. Eligible Sesame patients without insurance coverage could receive Zepbound at $349 (2.5mg) or $499 (5-15mg) per month. The move diversified Sesame's weight loss offerings beyond compounded drugs.
Sesame partners with Health-E Commerce for FSA/HSA store access
Health-E Commerce launched a collaboration making Sesame's mental health and dermatology services available on FSA Store and HSA Store. Dermatology services started at $59/month and mental health services at $79/month with unlimited messaging and video visits. The partnership allowed consumers to pay for Sesame services using pre-tax health savings accounts.
FDA warns telehealth firms over compounded GLP-1 advertising
The FDA and HHS announced a broad initiative to address misleading direct-to-consumer pharmaceutical advertisements, sending thousands of warning letters and approximately 100 cease-and-desist letters to companies with deceptive ads. Several GLP-1 telehealth providers were targeted. The regulatory action increased scrutiny on telehealth companies offering compounded weight loss drugs, including Sesame's market segment.
Sesame launches Wegovy pill through Novo Nordisk collaboration
Sesame partnered with Novo Nordisk as a NovoCare Recognized Care Provider to offer the newly FDA-approved Wegovy pill, the first oral GLP-1 for weight management. The comprehensive weight loss program started at $99/month with medication costs from $25/month for commercially insured patients or $149/month for self-pay. This shifted Sesame's weight loss business toward branded FDA-approved drugs.
Evidence (35 citations)
D1: User Value Erosion
D2: Business Customer Exploitation
D3: Shareholder Extraction
D4: Lock-in & Switching Costs
D5: Twiddling & Algorithmic Opacity
D6: Dark Patterns
D7: Advertising & Monetization Pressure
D8: Competitive Conduct
D9: Labor & Governance
D10: Regulatory & Legal Posture
Scoring Log (4 entries)
Stripped for Phase 2 re-enrichment